Skip to main content Skip to main navigation menu Skip to site footer

open access & Peer Reviewed

Combination of Gemcitabine and Docetaxel in Management of Leiomyosarcoma Metastasis

Monali Rajawat

Downloads

Download data is not yet available.

Abstract

Leiomyosarcoma is a type of soft tissue sarcoma which is a very tumor found in the human mankind. It is predominantly localized either in stomach, small intestine or retroperitoneum and often metastasizes to the distant parts like the lungs or liver. The main route of the metastasis is via the bloodstream, however, the lymphatics could also be used as a medium. The etiology of leiomyosarcoma (LMS) is yet unknown to men, but few studies has shown that genetic factors have an important role to play. The treatment options available for LMS metastasis (mets) in liver are very limited which ranges from chemotherapy, radiofrequency ablation and target therapy. Here I discuss a case of LMS mets to the liver managed by a combination therapy of Gemcitabine and Docetaxel.

Letter

Sir,

Leiomyosarcoma is a type of soft tissue sarcoma which is a very tumor found in the human mankind [1]. It is predominantly localized either in stomach, small intestine or retroperitoneum [2] and often metastasizes to the distant parts like the lungs or liver. The main route of the metastasis is via the bloodstream, however, the lymphatics could also be used as a medium. The etiology of leiomyosarcoma (LMS) is yet unknown to men, but few studies has shown that genetic factors have an important role to play [1]. The treatment options available for LMS metastasis (mets) in liver are very limited which ranges from chemotherapy, radiofrequency ablation and target therapy. Here I discuss a case of LMS mets to the liver managed by a combination therapy of Gemcitabine and Docetaxel.

A 47 year old patient came to the hospital having a mets of LMS to the liver (primary LMS was in stomach which was resected 2 years back). Post resection of the primary tumor from the stomach, the patient was put on doxorubicin (6 cycles) as a precautionary treatment. However, two years after I noticed mets (one large lesion of approximately 29x27 mm in right lobe and other small multiple lesions) in the liver. The patient was then once again put on Doxorubicin (2 cycles). However, the treatment did not work and the size of the largest lesion increased to 35x24 mm with an increment in the number of other lesions. Post the primary doxorubicin treatment, the patient was given 3 cycles of D-gemcitabine (1400mg) on day 1 followed by a combination of gemcitabine (1200 mg) with docetaxel (100mg) on day 8. Following this regimen, there was a considerable reduction in the number and size of other lesions/masses in the liver seen in USG. The patient was again put on 2 more cycles of the same regime and further there was a reduction in the size and number of lesions. Now the largest lesion had a size of only 24x23 mm.

Reduction in masses showed a ray of hope and the patient is again advised to undergo 2 more cycles of the same regime. Further, depending upon the condition of other lesions, radiofrequency ablation may be a viable option. Hence I suggest that more research should be done on this topic and more chemotherapeutic options should be available. Till then, a combination therapy of gemcitabine with docetaxel seems a good treatment regime for LMS mets.

References

  1. Leiomyosarcoma. National organization for rare disorders. Rare diseases. 2017;:-. View Article Google Scholar
  2. Piovanello P, Viola V, Costa G, Carletti M, Cecera A, Turchetta F, Iudicone R, Catalano G, Santucci A, Recchia F, Fiorillo L. Locally advanced leiomyosarcoma of the spleen: A case report and review of the literature. World journal of surgical oncology. 2007;5(1):135-. View Article Google Scholar
Author's Affiliation
Article Details

Issue: Vol 1 No 2 (2017)
Page No.: AY1-AY2
Published online: Apr 14, 2017
Section: Letter to the Editor
DOI: https://doi.org/10.5281/zenodo.546134

Copyright Info

Creative Commons License

Copyright: The Authors. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
How to Cite
Rajawat, M. (2017). Combination of Gemcitabine and Docetaxel in Management of Leiomyosarcoma Metastasis. Journal Of Medical Research And Innovation, 1(2), AY1-AY2. doi:10.5281/zenodo.546134
Downloading options
Article Statistics
HTML viewed = 500 times
PDF viewed = 45 times
XML viewed = 36 times